Please login to the form below

Not currently logged in
Email:
Password:

Glythera strengthens its scientific advisory board and appoints CSO

Dr Robert Lutz and Dr Jon Roffey join the UK biotech

Robert Lutz Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes.

Additionally, Dr Jon Roffey joins Glythera’s scientific advisory board (SAB) from Cancer Research Technology (CRT), Cancer Research UK’s commercial partnerships team, where he had been working since 2006.

Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s experience in ADC development will be a great asset as Glythera continued to develop our pipeline of cancer treatments.

“With his appointment as CSO, and the addition of Jon to our SAD, we start 2018 in a strengthened position as developers of the very best novel agents and targeted treatments, aiming to improve the lives of patients living with cancers that are the hardest to treat.”

23rd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics